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Vinflunine for Non-
small Cell Lung Cancer
Realistic Hopes?
To the Editor:
The enthusiasm of Tournoux-Facon
et al.1 for vinflunine for non-small cell
lung cancer needs comments.
In a phase III study, vinflunine has
not only showed similar efficacy end
points with docetaxel but also higher rates
of adverse effects in patients who have
experienced treatment failure with first-
line platinum-based chemotherapy.2
For advanced or metastatic transi-
tional cell carcinoma of the urothelial
tract, the European Medicines Agency
granted a marketing authorization for
vinflunine in June 2009 despite Bristol
had previously said it hoped to submit
the drug to the Food and Drug Admin-
istration in 2008 but gave up. However,
the National Institute for Clinical Excel-
lence (United Kingdom) has just pub-
lished (March 2011) its second negative
evaluation: Vinflunine is not recom-
mended.3 Indeed, the phase III study
showed neither significant (p  0.29)
nor relevant (2.3 months) change in me-
dian overall survival versus best sup-
portive care. Moreover, the incremental
cost-effectiveness ratio (£126,422) was
substantially more than the higher limit
considered as cost-effective.
Gemcitabine is approved by the
Food and Drug Administration in com-
bination with cisplatin for the first-line
treatment of patients (for whom surgery
is not possible) with locally advanced
(stage IIIA or IIIB) or metastatic (stage
IV or cancer that has spread) non-small
cell lung cancer.
The prerequisites to support the test-
ing of vinflunine in combination with
gemcitabine may be questioned.
Alain Braillon, MD, PhD
Gres. Public Health
Amiens, France
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Reply to the Letter to
the Editor Entitled
“Vinflunine for Non-small
Cell Lung Cancer:
Realistic Hopes?”
In Reply:
In his letter to the editor, Dr.
Braillon comments our “enthusiasm,”
which originally means inspiration or
possession by the presence of a god.
More modestly, the goal of our phase I
study was to determine a recommended
dose for vinflunine and gemcitabine.1
Beyond this semantic remark, his edito-
rial requires some scientific comments.
The phase III study to which Dr.
Braillon refers2 showed in fact similar
efficacy end points with docetaxel, a
standard treatment in second-line non-
small cell lung cancer (NSCLC). Re-
garding tolerability, he writes that vinfl-
unine has a “higher rate of adverse
events,” not mentioning that neuropathic
pain, alopecia, diarrhea, and nail disor-
ders were significantly more frequent
with docetaxel. The authors of this study
were slightly more accurate: “Despite
higher rates of some adverse events
(anemia, abdominal pain, constipation,
fatigue), the overall toxicity profile of
vinflunine was manageable.”
Regarding vinflunine for meta-
static or advanced transitional cell car-
cinoma of the urothelial tract after fail-
ure of a platinum-containing regimen,
Dr. Braillon is absolutely right when he
mentions that Bristol Myers Squibb
(BMS) gave up this development in the
United States. Pierre Fabre’s officials
explained to us that BMS made this
decision based on strictly strategic rea-
sons. BMS gave up before filing to Food
and Drug Administration, while Pierre
Fabre filed successfully to European
Medicines Agency (EMA), which is not
known for being less demanding than
Food and Drug Administration. Dr.
Braillon also refers to the fact that de-
spite EMA giving marketing authoriza-
tion for vinflunine on the basis of the
results of the phase III study,3 National
Institute for Health and Clinical Excel-
lence (NICE) does not recommend vin-
flunine in the United Kingdom. This
unfavorable assessment4 was based on
the results in the intent-to-treat popula-
tion and on cost-effectiveness, while
EMA based their approval on the eligi-
ble population. With the same logics,
NICE has also rejected the use of many
other anticancer agents that benefit to
numerous patients across the rest of the
European Union. This is the reason why
Pierre Fabre appealed NICE’s decision
and is still waiting for the final decision.
Dr. Braillon questions the ratio-
nale for combining vinflunine and gem-
citabine in first-line NSCLC. Vinflunine
has showed an activity in second-line
NSCLC similar to that of docetaxel, a
standard treatment. The combination of
cisplatin and vinflunine in first-line
NSCLC showed interesting results.5
Vinflunine acting on M and G2 phases
and gemcitabine on S phase, we consid-
ered that combining these two agents
might enhance their cytotoxic potential
in first-line NSCLC.
Jean-Marc Tourani, MD, PhD
Centre Hospitalier Universitaire–Poˆle
Re´gional de Cance´rologie
Poitiers, France
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